Civic Intelligence

T a G Treatment Action Group Inc.

990 • Fiscal year 2015 • EIN 13-3624785

Jan 01, 2015 to Dec 31, 2015 • Filed on Oct 26, 2016

Organization ProfileWWW.TREATMENTACTIONGROUP.ORG
90 Broad Street No 2503New York, NY 10004

(212) 253-7922

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

22nd percentile

0.01x

Higher debt load relative to assets than 22% of similar nonprofits.

2015 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2015

Liabilities / Revenue

20th percentile

0.01x

Higher debt load relative to revenue than 20% of similar nonprofits.

2015 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2015

Net Margin

23rd percentile

-8.4%

Higher net margin than 23% of similar nonprofits.

2015 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2015

Top Officer Pay

86th percentile

$169,389

Higher top officer pay than 86% of similar nonprofits.

Top officer pay equals 7.6% of source-year revenue.

2015 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2015

Asset Growth

21st percentile

-5.3%

Faster asset growth than 21% of similar nonprofits.

2015 filings • 501(c)3 • $1M-$5M nonprofits • Annualized from 2014 to 2015

Revenue Growth

5th percentile

-50%

Faster revenue growth than 5% of similar nonprofits.

2015 filings • 501(c)3 • $1M-$5M nonprofits • Annualized from 2014 to 2015

Balance Sheet
Liabilities / Assets22nd percentile

Assets

Down

$3,609,971

Down $201,269 (-5.3%) from 2014

Net Assets

Down

$3,589,237

Down $191,480 (-5.1%) from 2014

Liabilities

Down

$20,734

Down $9,789 (-32%) from 2014

Revenue And Expenses
Liabilities / Revenue20th percentileNet Margin23rd percentile

Revenue

Down

$2,230,880

Down $2,194,035 (-50%) from 2014

Expenses

Down

$2,419,194

Down $64,026 (-2.6%) from 2014

Net Income

Down

-$188,314

Down $2,130,009 (-110%) from 2014

Historical Trend

Balance Sheet Trend

Asset Growth21st percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$6.0M$4.0M$2.0M$0Assets 2010: $2,248,827Liabilities 2010: $2,860Net Assets 2010: $2,245,9672010Assets 2011: $2,679,042Liabilities 2011: $23,023Net Assets 2011: $2,656,0192011Assets 2012: $2,851,951Liabilities 2012: $25,636Net Assets 2012: $2,826,3152012Assets 2013: $1,880,235Liabilities 2013: $41,213Net Assets 2013: $1,839,0222013Assets 2014: $3,811,240Liabilities 2014: $30,523Net Assets 2014: $3,780,7172014Assets 2015: $3,609,971Liabilities 2015: $20,734Net Assets 2015: $3,589,2372015Assets 2016: $2,592,218Liabilities 2016: $74,083Net Assets 2016: $2,518,1352016Assets 2017: $2,575,844Liabilities 2017: $80,729Net Assets 2017: $2,495,1152017Assets 2018: $3,322,765Liabilities 2018: $67,916Net Assets 2018: $3,254,8492018Assets 2019: $2,736,460Liabilities 2019: $71,965Net Assets 2019: $2,664,4952019Assets 2020: $4,649,413Liabilities 2020: $282,097Net Assets 2020: $4,367,3162020Assets 2021: $3,776,196Liabilities 2021: $356,091Net Assets 2021: $3,420,1052021Assets 2022: $3,549,278Liabilities 2022: $931,291Net Assets 2022: $2,617,9872022Assets 2023: $4,624,032Liabilities 2023: $1,012,949Net Assets 2023: $3,611,0832023Assets 2024: $3,839,139Liabilities 2024: $745,777Net Assets 2024: $3,093,3622024

Highlighted filing

2015

Assets$3,609,971
Liabilities$20,734
Net Assets$3,589,237
Open 2015 Filing

Operations Trend

Revenue Growth5th percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$6.0M$4.0M$2.0M$0-$2.0MRevenue 2010: $1,912,416Expenses 2010: $2,198,624Net Income 2010: -$286,2082010Revenue 2011: $1,886,646Expenses 2011: $1,677,094Net Income 2011: $209,5522011Revenue 2012: $2,042,960Expenses 2012: $1,872,664Net Income 2012: $170,2962012Revenue 2013: $1,458,571Expenses 2013: $2,437,127Net Income 2013: -$978,5562013Revenue 2014: $4,424,915Expenses 2014: $2,483,220Net Income 2014: $1,941,6952014Revenue 2015: $2,230,880Expenses 2015: $2,419,194Net Income 2015: -$188,3142015Revenue 2016: $1,623,672Expenses 2016: $2,690,029Net Income 2016: -$1,066,3572016Revenue 2017: $2,619,130Expenses 2017: $2,642,336Net Income 2017: -$23,2062017Revenue 2018: $1,809,214Expenses 2018: $2,510,963Net Income 2018: -$701,7492018Revenue 2019: $2,174,190Expenses 2019: $2,764,544Net Income 2019: -$590,3542019Revenue 2020: $4,690,654Expenses 2020: $2,987,833Net Income 2020: $1,702,8212020Revenue 2021: $2,714,054Expenses 2021: $3,661,265Net Income 2021: -$947,2112021Revenue 2022: $2,911,955Expenses 2022: $3,714,073Net Income 2022: -$802,1182022Revenue 2023: $4,736,176Expenses 2023: $3,743,080Net Income 2023: $993,0962023Revenue 2024: $3,574,921Expenses 2024: $4,092,642Net Income 2024: -$517,7212024

Highlighted filing

2015

Revenue$2,230,880
Expenses$2,419,194
Net Income-$188,314
Open 2015 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2015 to Dec 31, 2015
Signed
Oct 26, 2016
Return Version
2015v2.1
Gross Receipts
$2,351,086
Mission and Program Overview

Mission

Tag works to ensure that all people with hiv, tb, or hcv receive lifesaving treatment, care, and information. Tag is science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. Tag catalyzes open collective action by all affected communities, scientists, and policy makers to end hiv, tb, and hcv.

See schedule o treatment action group ("tag") is a not-for-profit organization incorporated under the laws of the state of new york. Founded in 1992, tag is an independent aids research and policy think tank fighting for better treatment, a vaccine, and a cure for hiv/aids.

Balance Sheet Detail
LineBeginningEndChange
Assets
Savings and Temporary Cash Investments$1,210,200$2,961,238▲ $1,751,038
Accounts Receivable$2,163,115$171,984▼ $1,991,131
Prepaid Expenses and Deferred Charges$24,131$24,928▲ $797
Land, Buildings, and Equipment, Net$25,514$17,666▼ $7,848
Cash and Non-Interest-Bearing Accounts$2,765$10,140▲ $7,375
Total Assets$3,811,240$3,609,971▼ $201,269
Other Assets Total$385,515$424,015▲ $38,500
Liabilities
Accounts Payable and Accrued Expenses$30,523$20,734▼ $9,789
Total Liabilities$30,523$20,734▼ $9,789
Net Assets / Fund Balance
Temporarily Rstr Net Assets$2,676,891$1,939,851▼ $737,040
Unrestricted Net Assets$1,103,826$1,649,386▲ $545,560
Total Net Assets Fund Balance$3,780,717$3,589,237▼ $191,480
Total Liabilities and Net Assets / Fund Balance$3,811,240$3,609,971▼ $201,269

Asset Categories

AssetBook ValueDepreciationBasis
Equipment$17,666$62,019$79,685
Other Land Buildings$0$7,102$7,102
Other Assets Org$43,015--
Compensation and Service Providers
Top Officer Pay86th percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
Mark HarringtonExecutive DirectorFT$155,369$14,020$169,389
Scott W MorganDeputy Executive DirectorFT$119,366$24,309$143,675

Board Members and Trustees

NameTitle
Barbara HughesPresident
Alby P Maccarone JrDirector
David I SigalDirector
Frank BuaDirector
Frank RappaDirector
Jason OsherDirector
Jim AquinoDirector
Joy EpisallaDirector
Kevin GoetzDirector
Monte SteinmanDirector
Richard Lynn PhdDirector
Robert LennonDirector
Robert MonteleoneDirector
Roy M Gulick Md MphDirector
Earl L PlanteDirector (through 2/15)
Whitney M SogolDirector (through 7/15)
Laura MorrisonSecretary/treasurer
Revenue and Support

Revenue Composition

Contributions and Grants
$2,259,459
Program Service Revenue
$0
Investment Income
$2,096
Other Revenue
$-30,675
All Other Contributions
$2,068,373
Change in Net Assets
$-188,314

Noncash Contribution Practices

Property subject to holding requirements
No
Reviewed unusual noncash gifts
No
Third parties used for noncash contributions
No

Noncash Contributions

Contribution TypeContribution CountReported AmountValuation Method
Works of Art1$70,000Selling Value
Other Non Cash Contri Table52$43,379Selling Value
Total Noncash Contributions53$113,379-

Audited Revenue Reconciliation

Revenue per Audited Statements
$2,230,880
Revenue Not Reported on Financial Statements
$0
Revenue Not Reported on Form 990
$0
Total Revenue per Audited Statements
$2,230,880
Total Revenue per Form 990
$2,230,880
Expenses and Functional Allocation

Major Expense Lines

Line ItemAmount
Salaries, Compensation, and Employee Benefits$1,567,391
Other Expenses$818,586
Total Fundraising Expense$84,723
Grants and Similar Amounts Paid$33,217
Professional Fundraising Fees$0

Functional Expense Allocation

Line ItemProgramManagementFundraisingTotal
Other Salaries and Wages$976,375$17,786-$994,161
Current Officers, Directors, Trustees, and Key Employees$235,186$50,140$27,738$313,064
Travel$189,175$507-$189,682
Conferences and Meetings$183,000$1,000$1,138$185,138
Other Employee Benefits$152,319$5,451$2,381$160,151
Fees for Services Other$102,037$20,634$17,500$140,171
Payroll Taxes$89,378$8,515$2,122$100,015
Occupancy$92,213$5,196$2,046$99,455
Advertising$50,650$5,463$13,025$69,138
Office Expenses$36,349$22,702$4,958$64,009
Foreign Grants$33,217--$33,217
Information Technology$8,327$4,898$5,959$19,184
Fees for Services Accounting-$17,000-$17,000
Depreciation Depletion$4,198$4,266-$8,464
Insurance$1,737$6,094-$7,831
Fees for Services Legal-$3,990-$3,990
Fees for Services Lobbying$2,769--$2,769
Other Expenses$3,407$300$76$300
Total Functional Expenses$2,160,337$174,134$84,723$2,419,194

Audited Expense Reconciliation

Line ItemAmount
Expenses per Audited Statements$2,419,194
Total Expenses per Audited Statements$2,419,194
Total Expenses per Form 990$2,419,194
Expenses Not Reported on Financial Statements$0
Expenses Not Reported on Form 990$0
International Activity

International Summary

Offices
0
Employees
0
Spending
$264,166

International Compliance

Activity in boycott countries
No
Foreign corporation ownership
No
Foreign partnership interest
No
Interest in foreign trust
No
Passive foreign investment company interest
No
Transfers to foreign corporations
No

International Activities

RegionActivityServicesOfficesEmployeesSpending
South AfricaTb Cab and Iuatld Union Conference Cape Town November 2015Tb/hiv00$96,096
FranceConsultant Chloe Forette Hep Coaliton Website 2015Hcv Hepatitis00$18,000
CanadaIas World Aids Conference Vancouver Bc Canada July 2015Communications00$17,192
CanadaIas World Aids Conference Vancouver Bc Canada July 2015Tb/hiv00$15,689
FranceHcv Access Meeting Paris March 2015Hcv Hepatitis00$12,157
IndiaTag Tb Small Grants to Persons/organizations India 2015Tb/hiv00$11,469
IndiaPLANNING FOR GRANT-FUNDED CAB ONSITE VISITS INDIA DECEMBER 2015 [NOTE: ACTUAL TRIP IN JANUARY 2016]Tb/hiv00$6,973
CanadaIas World Aids Conference Vancouver Bc Canada July 2015Hcv Hepatitis00$6,613
MalaysiaIhrc Conference Kuala Lumpur October 2015Hcv Hepatitis00$6,370
AustraliaInhsu Conference Australia Oct. 2015Hcv Hepatitis00$5,870
AustriaEasl Conference Vienna April 2015Hcv Hepatitis00$5,716
PeruTag Tb Small Grants to Persons/organizations Peru 2015Tb/hiv00$4,642
FranceHcv Retreat Paimpol France Sept. 2015Hcv Hepatitis00$4,220
AustraliaReprint 2015 Tb Pipeline for Union Asia-pacific Mtg August 2015 AustraliaTb/hiv00$4,017
ThailandGenerics Meeting Bangkok May 2015Hcv Hepatitis00$3,780
CanadaIas World Aids Conference Vancouver Bc Canada July 2015Bsvc Basic Science Vaccine Cure00$3,724
IndiaDelhi Ip Conference December 2015Hcv Hepatitis00$3,452
FranceTreatment as Prevention Summit Paris October 2014Hiv Antiretrovirals00$3,286
ChinaShanghai Global Forum Tb Vaccines April 2015Tb/hiv00$3,253
SwitzerlandTb Ethics/rights Mtg Geneva May 2015Tb/hiv00$3,243
VietnamTag Tb Small Grants to Persons/organizations Viet Nam 2015Tb/hiv00$3,142
SwitzerlandWho Tb-stag Geneva June 2015Tb/hiv00$3,074
CanadaIas World Aids Conference Vancouver Bc Canada July 2015Hiv Antiretrovirals00$2,950
MoroccoMena Meeting & Report Morocco February 2015Hcv Hepatitis00$2,323
UkConsultant Fee Meera Senthilingam Dot Study Uk December 2015Tb/hiv00$2,000
UkGlobal Hep Summit Glasgow Uk Sept 2015Hcv Hepatitis00$1,737
SwitzerlandWho Guidelines Development Mtg Geneva November 2015Tb/hiv00$1,527
SpainContract Grupo De Trabajo Sobre Tratamientos Spain Translation Hcv Fact Sheets 2015Hcv Hepatitis00$1,389
UgandaTag Tb Small Grants to Persons/organizations Uganda 2015Tb/hiv00$1,293
SwitzerlandWho Tb Ethics Geneva November 2015Tb/hiv00$1,244
South AfricaConsultant Fee Tbonline to South Africa Development FundTb/hiv00$1,030
SpainTag Tb Small Grants to Persons/organizations Spain 2015Tb/hiv00$1,000
CanadaTb Nar Union Conference Vancouver Bc Canada February 2015Tb/hiv00$887
UkWorld Hepatitis Advocacy Mtg Uk February 2015Hcv Hepatitis00$826
BulgariaConsultant Ana Balkandjieva Contract Tb Online Weekly Newsletters 2015Tb/hiv00$648
UkHaart Meeting London December 2015Hcv Hepatitis00$580
SwitzerlandWho Stac-hep Meetings Geneva 2015Hcv Hepatitis00$471
CanadaAasld Meeting Vancouver Bc Canada November 2015Hcv Hepatitis00$384
SwitzerlandAnnual Member Dues International Aids Society Geneva October 2015Hiv Antiretrovirals00$369
SwitzerlandAnnual Member Dues International Aids Society Geneva October 2015Tb/hiv00$334
FranceAnnual Iuatld Member Dues Paris March 2015Tb/hiv00$280
SpainOsf Gfatm Mtg Barcelona April 2015Hcv Hepatitis00$193
UkAnnual Journal Subscription Renewals Jid and Cid Oxford Press, UkCommunications00$167
UkAnnual Journal Subscription Renewals Jid and Cid Oxford Press, UkTb/hiv00$151
UkraineConsultant Iryna Babanina Ukraine Russian Translation Hcv DocHcv Hepatitis00$141
UkAnnual Journal Subscription Renewals Jid and Cid Oxford Press, UkBsvc Basic Science Vaccine Cure00$120
UkraineUKRAINE ADVISORY BOARD MEETING, PWID/HIV+ SEPT 2015Hcv Hepatitis00$115
SwitzerlandAnnual Member Dues International Aids Society Geneva October 2015Bsvc Basic Science Vaccine Cure00$29
Fundraising, Events, and Gaming
Fundraising activities
Yes
Gaming activities
No
Professional fundraiser used
No

Fundraising and Gaming Totals

Line ItemAmount
Fundraising Direct Expenses$120,206
Fundraising Gross Income$54,750
Professional Fundraising Fees$0

Fundraising Events

EventGross ReceiptsGross RevenueDirect ExpensesNet Income
Riaa$244,186$54,750-$54,750
Total Events$244,186$54,750$119,541$-64,791
Political and Lobbying Activity
Political campaign activity
No
Lobbying activity
Yes
Subject to proxy tax
No
Insider Transactions and Loans

Interested-Person Transactions

Interested PartyRelationshipDescriptionShared RevenueAmount
Andrea Benzacar DaileyDomestic Partner of the Board PresidentEmploymentNo$88,681
Governance and Compliance

Governance Checklist

Compiled or reviewed by an accountant
No
Annual disclosure for covered persons
Yes
Audit committee
Yes
Business relationship with family members
Yes
Business relationship with organization members
No
Material changes to governing documents
Yes
Compensation from other sources disclosed
No
CEO compensation reviewed
Yes
Other officer compensation reviewed
Yes
Conflict-of-interest policy
Yes
Audited financial statements prepared
No
Key decisions subject to board approval
No
Management duties delegated
No

Governance Explanations

Form 990, Part VI, Section A, Line 4

“Treatment action group amended the by-laws in 2015. Key amendments were the medical leave policy for directors and the indemnification policy of the organization.”

Form 990, Part VI, Section B, Line 11

“A draft of form 990 was sent to members of the board of directors for review and approval. The audit committee reviewed the form 990 and reported to the executive committee and the board of trustees before the return was filed with the irs.”

Form 990, Part VI, Section B, Line 12C

“Conflict of interest policy requires board members and key staff to complete an annual disclosure statement. The related individual will be excluded from the discussion and the voting process.”

Form 990, Part VI, Section B, Line 15

“Compensation for key employees is reviewed and approved by the executive director. Compensation for the executive director is reviewed and approved by the board of directors.”

Form 990, Part VI, Section C, Line 19

“The organization's governing documents are available upon request. Annual reports are available on the organization's website.”

Filing and Contact Details

Filer

Filer Name
Treatment Action Group Inc
EIN
13-3624785
Phone
2122537922
Address
90 BROAD STREET NO 2503, NEW YORK, NY 10004

Signing Officer

Name
Laura Morrison
Title
Secretary/treasurer
Phone
2122537922
Signed
2016-10-26
Discuss with paid preparer
Yes

Organization Details

Principal Officer
Laura Morrison
Formed
1992
Legal Domicile
Ny
Voting Board Members
15
Independent Board Members
15
Employees
16
Volunteers
17

Preparer

Firm
Loeb & Troper Llp
Address
655 THIRD AVENUE 12TH FLOOR, NEW YORK, NY 10017
Preparer
Aaron Shapiro
Phone
2128674000
Supplemental Narrative

Additional Explanations

Form 990, Part XII, Line 2C

“The process has not changed since the prior year.”

Financial Statement Notes

PART III, LINE 4:

“The art prints are to be given to major donors of the "research in action awards" event.”

PART X, LINE 2:

“Tag has determined that there are no material uncertain tax positions that require recognition or disclosure in the financial statements. Periods ending december 31, 2012 and subsequent remain subject to examination by applicable taxing authorities.”

Raw XML AppendixShowing 400 of 955 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990/AccountantCompileOrReviewInd00
IRS990/AccountsPayableAccrExpnssGrp/BOYAmt030523
IRS990/AccountsPayableAccrExpnssGrp/EOYAmt020734
IRS990/AccountsReceivableGrp/BOYAmt02163115
IRS990/AccountsReceivableGrp/EOYAmt0171984
IRS990/ActivitiesConductedPrtshpInd00
IRS990/ActivityOrMissionDesc0SEE SCHEDULE O TREATMENT ACTION GROUP ("TAG") IS A NOT-FOR-PROFIT ORGANIZATION INCORPORATED UNDER THE LAWS OF THE STATE OF NEW YORK. FOUNDED IN 1992, TAG IS AN INDEPENDENT AIDS RESEARCH AND POLICY THINK TANK FIGHTING FOR BETTER TREATMENT, A VACCINE, AND A CURE FOR HIV/AIDS.
IRS990/AddressChangeInd0X
IRS990/AdvertisingGrp/FundraisingAmt013025
IRS990/AdvertisingGrp/ManagementAndGeneralAmt05463
IRS990/AdvertisingGrp/ProgramServicesAmt050650
IRS990/AdvertisingGrp/TotalAmt069138
IRS990/AllOtherContributionsAmt02068373
IRS990/AnnualDisclosureCoveredPrsnInd01
IRS990/AuditCommitteeInd01
IRS990/BooksInCareOfDetail/BusinessName/BusinessNameLine1Txt0SCOTT W MORGAN
IRS990/BooksInCareOfDetail/PhoneNum02122537922
IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt090 BROAD STREET
IRS990/BooksInCareOfDetail/USAddress/CityNm0NEW YORK
IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd0NY
IRS990/BooksInCareOfDetail/USAddress/ZIPCd010004
IRS990/BusinessRlnWithFamMemInd01
IRS990/BusinessRlnWithOfficerEntInd00
IRS990/BusinessRlnWithOrgMemInd00
IRS990/CashNonInterestBearingGrp/BOYAmt02765
IRS990/CashNonInterestBearingGrp/EOYAmt010140
IRS990/ChangeToOrgDocumentsInd01
IRS990/CntrctRcvdGreaterThan100KCnt00
IRS990/CollectionsOfArtInd01
IRS990/CompCurrentOfcrDirectorsGrp/FundraisingAmt027738
IRS990/CompCurrentOfcrDirectorsGrp/ManagementAndGeneralAmt050140
IRS990/CompCurrentOfcrDirectorsGrp/ProgramServicesAmt0235186
IRS990/CompCurrentOfcrDirectorsGrp/TotalAmt0313064
IRS990/CompensationFromOtherSrcsInd00
IRS990/CompensationProcessCEOInd01
IRS990/CompensationProcessOtherInd01
IRS990/ConferencesMeetingsGrp/FundraisingAmt01138
IRS990/ConferencesMeetingsGrp/ManagementAndGeneralAmt01000
IRS990/ConferencesMeetingsGrp/ProgramServicesAmt0183000
IRS990/ConferencesMeetingsGrp/TotalAmt0185138
IRS990/ConflictOfInterestPolicyInd01
IRS990/ConservationEasementsInd00
IRS990/ConsolidatedAuditFinclStmtInd00
IRS990/ContriRptFundraisingEventAmt0191086
IRS990/CreditCounselingInd00
IRS990/CYBenefitsPaidToMembersAmt00
IRS990/CYContributionsGrantsAmt02259459
IRS990/CYGrantsAndSimilarPaidAmt033217
IRS990/CYInvestmentIncomeAmt02096
IRS990/CYOtherExpensesAmt0818586
IRS990/CYOtherRevenueAmt0-30675
IRS990/CYProgramServiceRevenueAmt00
IRS990/CYRevenuesLessExpensesAmt0-188314
IRS990/CYSalariesCompEmpBnftPaidAmt01567391
IRS990/CYTotalExpensesAmt02419194
IRS990/CYTotalFundraisingExpenseAmt084723
IRS990/CYTotalProfFndrsngExpnsAmt00
IRS990/CYTotalRevenueAmt02230880
IRS990/DecisionsSubjectToApprovaInd00
IRS990/DeductibleArtContributionInd01
IRS990/DeductibleNonCashContriInd01
IRS990/DelegationOfMgmtDutiesInd00
IRS990/DepreciationDepletionGrp/ManagementAndGeneralAmt04266
IRS990/DepreciationDepletionGrp/ProgramServicesAmt04198
IRS990/DepreciationDepletionGrp/TotalAmt08464
IRS990/Desc0SEE SCHEDULE OTB/HIV PROJECT:TB KILLS ROUGHLY 1.3 MILLION PEOPLE EACH YEAR. DESPITE BEING CURABLE, IT IS THE LEADING CAUSE OF DEATH FOR HIV-POSITIVE PEOPLE GLOBALLY. HIV SIGNIFICANTLY INCREASES THE RISK FOR DEVELOPING TB DISEASE. PEOPLE AT RISK FOR BOTH DISEASES REQUIRE TB AND HIV SERVICES THAT WORK TOGETHER. TAG'S TB/HIV PROJECT STRENGTHENS COMMUNITY-DRIVEN ADVOCACY FOR BETTER TB/HIV RESEARCH, HIGH-QUALITY PROGRAMS, AND TB POLICIES WORLDWIDE. THE PROJECT EDUCATES, MOBILIZES, AND EMPOWERS HIV COMMUNITIES TO INCREASE COMMUNITY UNDERSTANDING OF TB/HIV COINFECTION AND TO TAKE ACTION TO REDUCE TB/HIV COINFECTION. THE PROJECT WORKS WITH RESEARCHERS, COMMUNITY ADVOCATES, POLICY MAKERS, AND GLOBAL COALITIONS TO INCREASE THE QUANTITY AND IMPROVE THE QUALITY OF RESEARCH THAT CAN LEAD TO BETTER TB TREATMENT AND PREVENTION; PRECISE DIAGNOSTICS; AND PREVENTIVE VACCINES.
IRS990/DescribedInSection501c3Ind01
IRS990/DisregardedEntityInd00
IRS990/DocumentRetentionPolicyInd01
IRS990/DonorAdvisedFundInd00
IRS990/ElectionOfBoardMembersInd00
IRS990/EmployeeCnt016
IRS990/EmploymentTaxReturnsFiledInd01
IRS990/EngagedInExcessBenefitTransInd00
IRS990/ExpenseAmt01045757
IRS990/FamilyOrBusinessRlnInd00
IRS990/FederalGrantAuditRequiredInd00
IRS990/FeesForServicesAccountingGrp/ManagementAndGeneralAmt017000
IRS990/FeesForServicesAccountingGrp/TotalAmt017000
IRS990/FeesForServicesLegalGrp/ManagementAndGeneralAmt03990
IRS990/FeesForServicesLegalGrp/TotalAmt03990
IRS990/FeesForServicesLobbyingGrp/ProgramServicesAmt02769
IRS990/FeesForServicesLobbyingGrp/TotalAmt02769
IRS990/FeesForServicesOtherGrp/FundraisingAmt017500
IRS990/FeesForServicesOtherGrp/ManagementAndGeneralAmt020634
IRS990/FeesForServicesOtherGrp/ProgramServicesAmt0102037
IRS990/FeesForServicesOtherGrp/TotalAmt0140171
IRS990/ForeignActivitiesInd01
IRS990/ForeignFinancialAccountInd00
IRS990/ForeignGrantsGrp/ProgramServicesAmt033217
IRS990/ForeignGrantsGrp/TotalAmt033217
IRS990/ForeignOfficeInd00
IRS990/Form8282PropertyDisposedOfInd00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt010.50
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt12.50
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt20.90
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt30.20
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt40.80
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt50.10
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt60.10
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt70.10
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt80.50
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt91.30
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt101.20
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt110.10
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt120.10
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt130.20
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt140.10
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt150.50
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt162.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt1740.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt1840.00
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd0X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd1X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd2X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd3X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd4X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd5X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd6X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd7X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd8X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd9X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd10X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd11X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd12X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd13X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd14X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd15X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd16X
IRS990/Form990PartVIISectionAGrp/OfficerInd0X
IRS990/Form990PartVIISectionAGrp/OfficerInd1X
IRS990/Form990PartVIISectionAGrp/OfficerInd2X
IRS990/Form990PartVIISectionAGrp/OfficerInd3X
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt00
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt10
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt20
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt30
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt40
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt50
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt60
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt70
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt80
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt90
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt100
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt110
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt120
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt130
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt140
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt150
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt160
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt1712889
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt1824309
IRS990/Form990PartVIISectionAGrp/PersonNm0BARBARA HUGHES
IRS990/Form990PartVIISectionAGrp/PersonNm1LAURA MORRISON
IRS990/Form990PartVIISectionAGrp/PersonNm2JIM AQUINO
IRS990/Form990PartVIISectionAGrp/PersonNm3FRANK BUA
IRS990/Form990PartVIISectionAGrp/PersonNm4JOY EPISALLA
IRS990/Form990PartVIISectionAGrp/PersonNm5KEVIN GOETZ
IRS990/Form990PartVIISectionAGrp/PersonNm6ROY M GULICK MD MPH
IRS990/Form990PartVIISectionAGrp/PersonNm7RICHARD LYNN PHD
IRS990/Form990PartVIISectionAGrp/PersonNm8ALBY P MACCARONE JR
IRS990/Form990PartVIISectionAGrp/PersonNm9ROBERT MONTELEONE
IRS990/Form990PartVIISectionAGrp/PersonNm10JASON OSHER
IRS990/Form990PartVIISectionAGrp/PersonNm11EARL L PLANTE
IRS990/Form990PartVIISectionAGrp/PersonNm12FRANK RAPPA
IRS990/Form990PartVIISectionAGrp/PersonNm13DAVID I SIGAL
IRS990/Form990PartVIISectionAGrp/PersonNm14WHITNEY M SOGOL
IRS990/Form990PartVIISectionAGrp/PersonNm15MONTE STEINMAN
IRS990/Form990PartVIISectionAGrp/PersonNm16ROBERT LENNON
IRS990/Form990PartVIISectionAGrp/PersonNm17MARK HARRINGTON
IRS990/Form990PartVIISectionAGrp/PersonNm18SCOTT W MORGAN
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt70
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt80
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt90
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt100
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt110
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt120
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt130
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt140
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt150
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt160
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt17156500
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt18119366
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt70
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt80
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt90
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt100
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt110
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt120
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt130
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt140
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt150
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt160
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt170
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt180
IRS990/Form990PartVIISectionAGrp/TitleTxt0PRESIDENT
IRS990/Form990PartVIISectionAGrp/TitleTxt1SECRETARY/TREASURER
IRS990/Form990PartVIISectionAGrp/TitleTxt2DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt3DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt4DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt5DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt6DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt7DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt8DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt9DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt10DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt11DIRECTOR (THROUGH 2/15)
IRS990/Form990PartVIISectionAGrp/TitleTxt12DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt13DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt14DIRECTOR (THROUGH 7/15)
IRS990/Form990PartVIISectionAGrp/TitleTxt15DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt16DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt17EXECUTIVE DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt18DEPUTY EXECUTIVE DIRECTOR
IRS990/Form990ProvidedToGvrnBodyInd01
IRS990/FormationYr01992
IRS990/FormerOfcrEmployeesListedInd00
IRS990/FSAuditedBasisGrp/SeparateBasisFinclStmtInd0X
IRS990/FSAuditedInd01
IRS990/FundraisingActivitiesInd01
IRS990/FundraisingAmt0191086
IRS990/FundraisingDirectExpensesAmt0120206
IRS990/FundraisingGrossIncomeAmt054750
IRS990/GamingActivitiesInd00
IRS990/GoverningBodyVotingMembersCnt015
IRS990/GrantAmt015717
IRS990/GrantsToIndividualsInd00
IRS990/GrantsToOrganizationsInd00
IRS990/GrantToRelatedPersonInd00
IRS990/GrossReceiptsAmt02351086
IRS990/GroupReturnForAffiliatesInd00
IRS990/IncludeFIN48FootnoteInd01
IRS990/IndependentAuditFinclStmtInd01
IRS990/IndependentVotingMemberCnt015
IRS990/IndivRcvdGreaterThan100KCnt02
IRS990/IndoorTanningServicesInd00
IRS990/InfoInScheduleOPartIIIInd0X
IRS990/InfoInScheduleOPartVIInd0X
IRS990/InfoInScheduleOPartXIIInd0X
IRS990/InformationTechnologyGrp/FundraisingAmt05959
IRS990/InformationTechnologyGrp/ManagementAndGeneralAmt04898
IRS990/InformationTechnologyGrp/ProgramServicesAmt08327
IRS990/InformationTechnologyGrp/TotalAmt019184
IRS990/InsuranceGrp/ManagementAndGeneralAmt06094
IRS990/InsuranceGrp/ProgramServicesAmt01737
IRS990/InsuranceGrp/TotalAmt07831
IRS990/InvestmentIncomeGrp/ExclusionAmt02096
IRS990/InvestmentIncomeGrp/TotalRevenueColumnAmt02096
IRS990/InvestmentInJointVentureInd00
IRS990/IRPDocumentCnt06
IRS990/IRPDocumentW2GCnt00
IRS990/LandBldgEquipAccumDeprecAmt069121
IRS990/LandBldgEquipBasisNetGrp/BOYAmt025514
IRS990/LandBldgEquipBasisNetGrp/EOYAmt017666
IRS990/LandBldgEquipCostOrOtherBssAmt086787
IRS990/LegalDomicileStateCd0NY
IRS990/LoanOutstandingInd00
IRS990/LobbyingActivitiesInd01
IRS990/LocalChaptersInd00
IRS990/MaterialDiversionOrMisuseInd00
IRS990/MembersOrStockholdersInd00
IRS990/MethodOfAccountingAccrualInd0X
IRS990/MinutesOfCommitteesInd01
IRS990/MinutesOfGoverningBodyInd01
IRS990/MissionDesc0TAG WORKS TO ENSURE THAT ALL PEOPLE WITH HIV RECEIVE LIFESAVING TREATMENT, CARE, AND INFORMATION. WE ARE SCIENCE-BASED TREATMENT ACTIVISTS WORKING TO EXPAND AND ACCELERATE VITAL RESEARCH AND EFFECTIVE COMMUNITY ENGAGEMENT WITH RESEARCH AND POLICY INSTITUTIONS. TAG CATALYZES OPEN COLLECTIVE ACTION BY ALL AFFECTED COMMUNITIES, SCIENTISTS, AND POLICY MAKERS, AND GLOBAL COALITIONS, TO INCREASE THE QUATITY, AND IMPROVE THE QUALITY OF RESEARCH, THAT CAN LEAD TO BETTER TUBERCULOSIS (TB) TREATMENT AND PREVENTION; PRECISE DIAGNOSTICS; AND PREVENTIVE VACCINES.
IRS990/MoreThan5000KToIndividualsInd01
IRS990/MoreThan5000KToOrgInd00
IRS990/NetAssetsOrFundBalancesBOYAmt03780717
IRS990/NetAssetsOrFundBalancesEOYAmt03589237
IRS990/NetIncmFromFundraisingEvtGrp/ExclusionAmt0-65456
IRS990/NetIncmFromFundraisingEvtGrp/TotalRevenueColumnAmt0-65456
IRS990/NetUnrelatedBusTxblIncmAmt00
IRS990/NoncashContributionsAmt0113379
IRS990/NondeductibleContributionsInd00
IRS990/OccupancyGrp/FundraisingAmt02046
IRS990/OccupancyGrp/ManagementAndGeneralAmt05196
IRS990/OccupancyGrp/ProgramServicesAmt092213
IRS990/OccupancyGrp/TotalAmt099455
IRS990/OfficeExpensesGrp/FundraisingAmt04958
IRS990/OfficeExpensesGrp/ManagementAndGeneralAmt022702
IRS990/OfficeExpensesGrp/ProgramServicesAmt036349
IRS990/OfficeExpensesGrp/TotalAmt064009
IRS990/OfficerMailingAddressInd00
IRS990/OperateHospitalInd00
IRS990/Organization501c3Ind0X
IRS990/OrganizationFollowsSFAS117Ind0X
IRS990/OtherAssetsTotalGrp/BOYAmt0385515
IRS990/OtherAssetsTotalGrp/EOYAmt0424015
IRS990/OtherChangesInNetAssetsAmt0-3166
IRS990/OtherEmployeeBenefitsGrp/FundraisingAmt02381
IRS990/OtherEmployeeBenefitsGrp/ManagementAndGeneralAmt05451
IRS990/OtherEmployeeBenefitsGrp/ProgramServicesAmt0152319
IRS990/OtherEmployeeBenefitsGrp/TotalAmt0160151
IRS990/OtherExpensesGrp/Desc0OTHER
IRS990/OtherExpensesGrp/Desc1MOVING EXPENSES
IRS990/OtherExpensesGrp/Desc2BAD DEBT
IRS990/OtherExpensesGrp/FundraisingAmt07780
IRS990/OtherExpensesGrp/FundraisingAmt176
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt0192
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt1300
IRS990/OtherExpensesGrp/ProgramServicesAmt03407
IRS990/OtherExpensesGrp/TotalAmt07780
IRS990/OtherExpensesGrp/TotalAmt13675
IRS990/OtherExpensesGrp/TotalAmt2300
IRS990/OtherRevenueMiscGrp/BusinessCd0900099
IRS990/OtherRevenueMiscGrp/Desc0OTHER
IRS990/OtherRevenueMiscGrp/ExclusionAmt034781
IRS990/OtherRevenueMiscGrp/TotalRevenueColumnAmt034781
IRS990/OtherRevenueTotalAmt034781
IRS990/OtherSalariesAndWagesGrp/ManagementAndGeneralAmt017786
IRS990/OtherSalariesAndWagesGrp/ProgramServicesAmt0976375
IRS990/OtherSalariesAndWagesGrp/TotalAmt0994161
IRS990/PartialLiquidationInd00
IRS990/PayPremiumsPrsnlBnftCntrctInd00
IRS990/PayrollTaxesGrp/FundraisingAmt02122
IRS990/PayrollTaxesGrp/ManagementAndGeneralAmt08515
IRS990/PayrollTaxesGrp/ProgramServicesAmt089378
IRS990/PayrollTaxesGrp/TotalAmt0100015
IRS990/PoliticalCampaignActyInd00
IRS990/PrepaidExpensesDefrdChargesGrp/BOYAmt024131
IRS990/PrepaidExpensesDefrdChargesGrp/EOYAmt024928
IRS990/PrincipalOfficerNm0LAURA MORRISON
IRS990/ProfessionalFundraisingInd00
IRS990/ProgSrvcAccomActy2Grp/Desc0SEE SCHEDULE OHIV PROJECT:EACH YEAR, APPROXIMATELY 1.2 MILLION PEOPLE WORLDWIDE DIE OF HIV DISEASE. THIS IMMENSE PUBLIC HEALTH FAILURE CAN BE ATTRIBUTED TO A DENSE WEB OF MEDICAL, POLITICAL, AND ECONOMIC PROBLEMS. THE VAST MAJORITY OF THE WORLD'S 35 MILLION HIV-POSITIVE PEOPLE LIVE IN POOR COUNTRIES WHERE MANY OBSTACLES PREVENT THE WIDESPREAD DISTRIBUTION OF HIV DRUGS. BUT EVEN THE MOST EFFECTIVE EXISTING DRUGS HAVE MAJOR SHORTCOMINGS, AND HIV-POSITIVE PEOPLE EVERYWHERE NEED BETTER TREATMENT STRATEGIES AND, ULTIMATELY, A CURE-ONE THAT IS SCALABLE, AFFORDABLE, AND CAN BE USED WORLDWIDE TO END THE EPIDEMIC ALONG WITH A SAFE AND EFFECTIVE HIV VACCINE. TAG'S HIV PROJECT REVIEWS THE STATE OF RESEARCH ON ANTI-HIV DRUG DISCOVERY, DEVELOPMENT, DISSEMINATION, AND POSTMARKETING SURVEILLANCE. THE HIV PROJECT ADVOCATES FOR ACCELERATED ACCESS TO TREATMENTS; INNOVATION IN THE DEVELOPMENT OF TREATMENTS THAT ARE ACTIVE AGAINST DRUG-RESISTANT HIV; AND DEVELOPMENT OF HIV TREATMENTS THAT ARE EASIER TO TAKE, LESS TOXIC, OR REPRESENT A MAJOR THERAPEUTIC BREAKTHROUGH SUCH AS A NEW DRUG CLASS. THE PROJECT ADVOCATES FOR BETTER POSTMARKETING RESEARCH ON APPROVED ANTIRETROVIRAL DRUGS TO IMPROVE STANDARDS OF CARE; WORKS ON DOMESTIC AND INTERNATIONAL TREATMENT GUIDELINES; AND EDUCATES AND MOBILIZES POLICY MAKERS, RESEARCHERS, AND THE HIV COMMUNITY ON HIV TREATMENT RESEARCH. TAG'S HIV PROJECT WORKS WITH COMMUNITY MEMBERS, SCIENTISTS, AND POLICY MAKERS TO ENHANCE PUBLIC UNDERSTANDING OF THE SCIENCE OF HIV INFECTION, ADDRESS GAPS IN HIV RESEARCH, CRITIQUE RESEARCH EFFORTS, AND FOSTER CROSS-DISCIPLINARY COLLABORATIONS WITH THE AIM OF ACCELERATING RESEARCH ON HIV PATHOGENESIS AND THE DEVELOPMENT OF EFFECTIVE IMMUNE-BASED THERAPIES AND PREVENTIVE TECHNOLOGIES, WITH A PARTICULAR FOCUS ON RESEARCH ADVOCACY AROUND A CURE FOR HIV.THE HIV PROJECT TRACKS AND ANALYZES RESOURCES DEVOTED TO HIV PREVENTION AND COMBINED PREVENTION TECHNOLOGIES. THE PROJECT ADVOCATES FOR LOCAL, STATE, AND NATIONAL AGENCIES AND AIDS SERVICE ORGANIZATIONS TO HAVE INCREASED AWARENESS OF CURRENT PREVENTION TOOLS IN ORDER TO STOP TRANSMISSION OF HIV AND THUS END THE EPIDEMIC. PROJECT MEMBERS WORKED ON GOVERNOR CUOMO'S TASK FORCE TO END AIDS IN NEW YORK STATE BY 2020. THIS EFFORT IS PART OF A BROADER PROJECT BY COMMUNITY ACTIVISTS, POLICY MAKERS, ADVOCATES, AND RESEARCHERS TO END THE EPIDEMIC BY STEMMING NEW INFECTIONS AND ENSURING THAT HIV-POSITIVE PEOPLE RECEIVE CARE, ARE RETAINED IN ACTIVE CARE, AND REMAIN VIRALLY SUPPRESSED. TAG'S HIV PROJECT HAS BEEN LOOKING AT A COHORT OF CASE STUDIES ON BEST PRACTICES IN COMMUNITY MOBILIZATION AND HOW THEY AFFECT THE TREATMENT AND CARE OF BOTH PEOPLE WITH HIV AND THOSE WHO ARE HIV-NEGATIVE.FINALLY, THE HIV PROJECT WORKS WITH GLOBAL AND DOMESTIC PARTNERS FOR UNIVERSAL ACCESS TO HIGH-QUALITY HIV PREVENTION, TREATMENT, AND CARE PROGRAMS.
IRS990/ProgSrvcAccomActy2Grp/ExpenseAmt0514502
IRS990/ProgSrvcAccomActy2Grp/GrantAmt017500
IRS990/ProgSrvcAccomActy3Grp/Desc0SEE SCHEDULE OHEPATITIS C-RELATED LIVER DISEASE IS A LEADING CAUSE OF DEATH AMONG HIV-POSITIVE PEOPLE IN THE UNITED STATES AND EUROPE. GLOBALLY, 5 MILLION HIV-POSITIVE PEOPLE ARE COINFECTED WITH THE HEPATITIS C VIRUS (HCV), WHILE OVER 175 MILLION HAVE HCV ALONE. HIV WORSENS HCV DISEASE PROGRESSION AND OUTCOMES. TAG'S HEPATITIS/HIV PROJECT REVIEWS THE STATE OF RESEARCH ON HCV MONOINFECTION AND COINFECTION. IT ADVOCATES FOR BETTER AND SAFER TREATMENTS, BETTER CLINICAL TRIAL DESIGNS, AND ACCESS TO CURATIVE TREATMENT FOR ALL AFFECTED COMMUNITIES, AND IT CONTINUALLY MONITORS STANDARDS OF CARE FOR PEOPLE WITH HCV MONOINFECTION AND COINFECTION. THE PROJECT WORKS IN COLLABORATION WITH THE HCV AND HIV COMMUNITIES, SCIENTISTS, GOVERNMENT, AND DRUG COMPANIES TO PROVIDE LIFESAVING INFORMATION AND SAFER, MORE TOLERABLE, AND CURATIVE HEPATITIS TREATMENTS UNIVERSALLY AVAILABLE. IN 2012, THE PROJECT EXPANDED ITS SCOPE TO TAKE ON THE CHALLENGE OF ACCELERATING INTERNATIONAL ACCESS TO CUTTING-EDGE TREATMENT FOR HCV. WITH THE ADVENT OF NEW SHORT-COURSE ALL-ORAL CURES FOR HCV, THE PROJECT HAS BEEN COLLABORATING WITH PARTNERS GLOBALLY TO HASTEN UNIVERSAL, AFFORDABLE ACCESS TO THESE CURATIVE DRUGS. IN 2014, THE PROJECT WAS INSTRUMENTAL IN BUILDING A GLOBAL COALITION OF ACTIVISTS IN LOW- AND MIDDLE-INCOME COUNTRIES WHO ARE ADVOCATING FOR ACCESS TO THESE CURES AND FOR CARE FOR ALL PEOPLE WITH HCV. IN 2015, A HANDFUL OF COUNTRIES, SUCH AS EGYPT AND GEORGIA - AND ORGANIZATIONS SUCH AS M DECINS SANS FRONTI RES (MSF) - LAUNCHED NATIONAL OR LOCAL HCV TREATMENT PROJECTS WITH DIRECT ACTIVE ANTIVIRALS (DAAS). BUT MOST COUNTRIES, COULD NOT AFFORD TO INITIATE TREATMENT PROGRAMS WITH DAAS - OR EVEN WITH PEGYLATED INTERFERON AND RIBAVIRIN (A LESS EFFECTIVE, MORE TOXIC TREATMENT REGIMEN). WITHOUT ACCESS TO AFFORDABLE, HIGH-QUALITY GENERIC DAAS, GLOBAL TARGETS TO REDUCE HCV INCIDENCE AND MORTALITY WILL BE UNATTAINABLE. MOST PEOPLE IN NEED OF HCV TREATMENT WILL REMAIN UNTREATED - AND THE EPIDEMIC WILL CONTINUE TO SPREAD. COMMUNITY EDUCATION, ORGANIZING AND EMPOWERMENT ARE A PREREQUISITE FOR SUCCESSFUL AND SUSTAINABLE ADVOCACY. WITH HEPATITIS C, POLITICAL WILL AND RESOURCE MOBILIZATION ARE NEEDED AT THE HIGHEST LEVELS - INCLUDING UNITED NATIONS (UN) AGENCIES SUCH AS THE WORLD HEALTH ORGANIZATION (WHO) AND PRESSURE MUST BE KEPT ON ORIGINATOR COMPANIES, TO ACHIEVE PRICE REDUCTIONS AND REMOVE OTHER ACCESS BARRIERS. TAG'S HEPATITIS/HIV PROJECT HAS BEEN AT THE FOREFRONT OF A GLOBAL HCV TREATMENT ACCESS EDUCATION AND ADVOCACY MOVEMENT.
IRS990/ProgSrvcAccomActy3Grp/ExpenseAmt0424976
IRS990/ProgSrvcAccomActyOtherGrp/Desc0CURE PROJECT:TAG'S BASIC SCIENCE, VACCINES, AND CURE (BSVC) PROJECT BRINGS TOGETHER BASIC AND CLINICAL SCIENTISTS, GOVERNMENT OFFICIALS, REGULATORS, RESEARCHERS, AND COMMUNITY ADVOCATES TO INCREASE FUNDING FOR AND ATTENTION TO BASIC AND CLINICAL SCIENCE THAT WILL LEAD TO AN HIV CURE. THE PURSUIT OF A CURE FOR HIV INFECTION IS NOW A CENTRAL ELEMENT OF THE RESEARCH EFFORT, A TESTAMENT TO THE REMARKABLE SCIENTIFIC PROGRESS THAT HAS OCCURRED OVER THE PAST THREE DECADES. ACHIEVING A CURE IS OF CRITICAL IMPORTANCE FOR HIV-POSITIVE PEOPLE AND FOR REALIZING THE GOAL OF ULTIMATELY ENDING THE PANDEMIC. TAG CONTINUES TO EXPAND OUR ADVOCACY AND EDUCATION WORK RELATED TO HIV CURE RESEARCH ON SEVERAL FRONTS:PROVISION OF RESOURCES AND EDUCATIONAL MATERIALS VIA THE TAG WEBSITE AND SOCIAL MEDIA. RESOURCES INCLUDE: A REGULARLY UPDATED LISTING OF CURE RESEARCH-RELATED CLINICAL TRIALS AND OBSERVATIONAL STUDIES THAT HAS BECOME A WIDELY USED REFERENCE. THE BSVC PROJECT BLOG AND TWITTER FEED, WHICH REPORTS AND COMMENTS ON NEW DEVELOPMENTS IN THE FIELD, INCLUDING PUBLISHED SCIENTIFIC PAPERS AND CONFERENCE PRESENTATIONS. TAG'S CURE RESEARCH MEDIA MONITOR PAGE, WHICH PROVIDES BACKGROUND, CONTEXT AND COMMENTARY ON HIGH PROFILE BUT POTENTIALLY MISLEADING MAINSTREAM NEWS STORIES ON CURE RESEARCH - A BURGEONING PROBLEM AS THE RESEARCH ATTRACTS MORE PUBLICITY. CURE RESEARCH FACT SHEET. COMMUNITY GUIDELINES ON THE USE OF ANTIRETROVIRAL TREATMENT INTERRUPTIONS IN CURE RESEARCH. THE RESEARCH TOWARD A CURE AND IMMUNE-BASED AND GENE THERAPIES CHAPTER OF TAG'S ANNUAL PIPELINE REPORT. LINKS TO KEY ARTICLES AND INFORMATION ON CURE RESEARCH, INCLUDING COMMUNITY-BASED NEWS SOURCES AND OPEN ACCESS SCIENTIFIC PUBLICATIONS.PROVIDING COMMUNITY INPUT INTO CURE RESEARCH PROCESSES, DRAWING ON TAG'S LONG HISTORY AS A LEADER IN HIV RESEARCH ADVOCACY. TAG PARTICIPATES IN MULTIPLE COLLABORATIVE PROJECTS, INCLUDING: THE INTERNATIONAL AIDS SOCIETY (IAS) TOWARDS AN HIV CURE INTERNATIONAL SCIENTIFIC WORKING GROUP, WHICH IS CURRENTLY UPDATING THE IAS TOWARDS AN HIV CURE GLOBAL STRATEGY RECOMMENDATIONS FOR RELEASE AT THE INTERNATIONAL AIDS CONFERENCE IN DURBAN IN 2016. THE FORUM FOR COLLABORATIVE HIV RESEARCH HIV CURE PROJECT, WHICH IS WORKING TO ADDRESS THE REGULATORY CHALLENGES INVOLVED IN CURE RESEARCH. THE COMMUNITY ADVISORY BOARDS (CABS) FOR THE MARTIN DELANEY COLLABORATORYS, WHICH CURRENTLY CONSIST OF THREE LARGE COLLABORATIONS FOCUSED ON HIV CURE RESEARCH (FUNDED PRIMARILY BY THE US NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES). TAG'S BSVC PROJECT DIRECTOR RICHARD JEFFERYS IS A MEMBER OF THE DARE COLLABORATORY CAB AND THE NATIONAL CAB WHICH CONSISTS OF REPRESENTATIVES FROM EACH INDIVIDUAL COLLABORATORY CAB (DARE, CARE AND DEFEATHIV). THE NATIONAL CAB IS CURRENTLY PROVIDING RECOMMENDATIONS FOR FACILITATING COMMUNITY INPUT INTO THE NEXT ROUND OF MARTIN DELANEY COLLABORATORY GRANTS, WHICH WILL BE FUNDED IN 2016. THE RESEARCH WORKING GROUP OF THE FEDERAL AIDS POLICY PARTNERSHIP, WHICH FOCUSES ON INCREASING SUPPORT FOR SCIENTIFIC RESEARCH AND ADDRESSING THE RECENT DECLINE IN FUNDING (IN REAL TERMS) FOR THE NATIONAL INSTITUTES OF HEALTH. TAG'S BSVC PROJECT DIRECTOR RICHARD JEFFERYS IS A MEMBER OF AMFAR'S CURE COUNCIL, WHICH PROVIDES OVERSIGHT OF AMFAR'S EXTENSIVE FUNDING SUPPORT FOR CURE RESEARCH. MEMBERSHIP OF THE STEERING COMMITTEE FOR THE CURRICULUM PROJECT, A COLLABORATIVE ENDEAVOR OF AVAC, THE MARTIN DELANEY COLLABORATORYS, NAPWHA AUSTRALIA, PROJECT INFORM AND SIDACTION. THE CURRICULUM COMPRISES EDUCATIONAL MODULES ON KEY TOPICS IN HIV CURE RESEARCH, WITH TAG CONTRIBUTING MODULES ON THERAPEUTIC VACCINES/IMMUNE-BASED THERAPIES AND BASIC SCIENCE, AND PRESENTING ON THESE CURRICULUM WEBINARS.
IRS990/ProgSrvcAccomActyOtherGrp/Desc1CROSS-PROJECT FUNCTIONS (COMMUNICATIONS AND ADVOCACY, U.S. AND GLOBALHEALTH POLICY PROJECT):TAG ADVOCATES FOR INCREASED U.S. GOVERNMENT FUNDING FOR RESEARCH ANDDEVELOPMENT THAT CAN LEAD TO MORE EFFECTIVE AND MORE ACCESSIBLEPREVENTION, DIAGNOSIS, TREATMENT, OR VACCINES FOR HIV/AIDS, HCV, ANDTB. TAG'S PROJECTS WORK IN COLLABORATION WITH GLOBAL HEALTH COALITIONSTO ENSURE EFFECTIVE GLOBAL HIV/AIDS, HCV, AND TB PROGRAMS. TAG WORKSWITH GLOBAL HEALTH ADVOCATES AND ACTIVISTS IN OTHER DONOR ANDDEVELOPING COUNTRIES TO PROMOTE AND ADVANCE A COMMON AGENDA OFUNIVERSAL ACCESS TO HIGH-QUALITY, AFFORDABLE, AND EQUITABLE HEALTH CARESERVICES. EACH TAG PROJECT CREATES AND PUBLISHES NEWSLETTERS,PROJECT-SPECIFIC PUBLICATIONS, BRIEFS, PRESENTATIONS, OR TOOLKITS THATCAN BE USED FOR THE PURPOSES OF EDUCATION, ADVOCACY, COALITION BUILDING, AND ADVANCING RESEARCH. TAG'S FLAGSHIP PUBLICATION, THEPIPELINE REPORT, ANNUALLY DOCUMENTS AND CRITIQUES THE STATE OF CURRENTTREATMENTS AND THE DEVELOPMENT OF NEW TREATMENTS, VACCINES, ANDDIAGNOSTICS FOR THE DISEASE AREAS COVERED BY TAG'S PROJECTS. SINCE1994, TAG HAS ALSO REGULARLY PUBLISHED ITS COMMUNITY-BASED TREATMENTADVOCACY MAGAZINE, TAGLINE, PROVIDING DONORS, RESEARCHERS, ADVOCATES,AND PEOPLE WITH HIV/AIDS, HCV, AND TB WITH ESSENTIAL NEWS, ANALYSIS, AND ORGANIZING INFORMATION ABOUT RELEVANT ISSUES OF POLICY AND SCIENCE.TAG'S WEBSITE PROVIDES ACCESS TO ALL TAG PUBLICATIONS, FREE OF CHARGE,FOR DOWNLOAD ANYWHERE IN THE WORLD. THE WEBSITE INCLUDES PROJECTUPDATES AS WELL AS INFORMATION ON RELEVANT EVENTS AND CONFERENCES,PRESS RELEASES, PAST NEWSLETTERS, ANNUAL REPORTS, AND ANALYSES OFDEVELOPMENTS IN TAG'S PROJECT AREAS.TAG EDUCATES COMMUNITIES AFFECTED BY HIV/AIDS, HCV, AND TB AROUND THEUNITED STATES AND THROUGHOUT THE WORLD ABOUT THE LATEST DEVELOPMENTS INRESEARCH, PREVENTION, AND TREATMENT. TAG ALSO TRAINS AND MENTORSLEADERS OF COMMUNITY-BASED ORGANIZATIONS AND NETWORKS TO STRENGTHENTHEIR ADVOCACY AND SCIENTIFIC LITERACY AROUND HIV/AIDS, HCV, AND TB.TAG WORKS WITH INDIVIDUALS AND ORGANIZATIONS WORLDWIDE TO SPUR THEDEVELOPMENT OF MORE EFFECTIVE GLOBAL INTERVENTIONS AGAINST HIV/AIDS,HCV, AND TB, AND TO STRENGTHEN TREATMENT EDUCATION AND LITERACY EFFORTSIN DEVELOPING COUNTRIES.IN 2015, EXPENSES FOR THE COMMUNICATIONS AND ADVOCACY PROGRAM WEREALLOCATED AMONG ALL OTHER PROGRAMS.
IRS990/ProgSrvcAccomActyOtherGrp/ExpenseAmt0163553
IRS990/ProgSrvcAccomActyOtherGrp/ExpenseAmt111549
IRS990/ProhibitedTaxShelterTransInd00
IRS990/PYBenefitsPaidToMembersAmt00
IRS990/PYContributionsGrantsAmt04468799
IRS990/PYExcessBenefitTransInd00
IRS990/PYGrantsAndSimilarPaidAmt00
IRS990/PYInvestmentIncomeAmt02457
IRS990/PYOtherExpensesAmt0918212
IRS990/PYOtherRevenueAmt0-46341
IRS990/PYProgramServiceRevenueAmt00
IRS990/PYRevenuesLessExpensesAmt01941695
IRS990/PYSalariesCompEmpBnftPaidAmt01565008
IRS990/PYTotalExpensesAmt02483220
IRS990/PYTotalProfFndrsngExpnsAmt00
IRS990/PYTotalRevenueAmt04424915
IRS990/QuidProQuoContributionsInd01
IRS990/QuidProQuoContriDisclInd01
IRS990/RcvFndsToPayPrsnlBnftCntrctInd00
IRS990/ReconcilationRevenueExpnssAmt0-188314
IRS990/RegularMonitoringEnfrcInd01
IRS990/RelatedEntityInd00
IRS990/RelatedOrganizationCtrlEntInd00
IRS990/ReportInvestmentsOtherSecInd00
IRS990/ReportLandBuildingEquipmentInd01
IRS990/ReportOtherAssetsInd01
IRS990/ReportOtherLiabilitiesInd00
IRS990/ReportProgramRelatedInvstInd00
IRS990/SavingsAndTempCashInvstGrp/BOYAmt01210200
IRS990/SavingsAndTempCashInvstGrp/EOYAmt02961238
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt02294240
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt04468799
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt01490224
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt02112847
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt01992591
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt012358701
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt02096
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus1YearAmt02457
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus2YearsAmt02815
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus3YearsAmt04687
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus4YearsAmt05851
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt017906
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.51150
IRS990ScheduleA/PublicSupportPY170Pct00.45590
IRS990ScheduleA/PublicSupportTotal170Amt06330694
IRS990ScheduleA/SubstantialContributorsTotAmt06028007
IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt02294240
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt04468799
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt01490224
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt02112847
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt01992591
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt012358701
IRS990ScheduleA/TotalSupportAmt012376607
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2015 • Form 990Detailed filing. Detailed filing data is available for this year.

Open filing
Assets
$3,609,971
Liabilities
$20,734
Net assets
$3,589,237
Revenue
$2,230,880
Expenses
$2,419,194
Net income
-$188,314
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Facts available. Structured filing facts are available, but richer extracted sections are limited.$3.84$0.75$3.09$3.57$4.09$0.52
2023Detailed filing. Detailed filing data is available for this year.$4.62$1.01$3.61$4.74$3.74$0.99
2022Detailed filing. Detailed filing data is available for this year.$3.55$0.93$2.62$2.91$3.71$0.80
2021Detailed filing. Detailed filing data is available for this year.$3.78$0.36$3.42$2.71$3.66$0.95
2020Detailed filing. Detailed filing data is available for this year.$4.65$0.28$4.37$4.69$2.99$1.70
2019Detailed filing. Detailed filing data is available for this year.$2.74$0.07$2.66$2.17$2.76$0.59
2018Detailed filing. Detailed filing data is available for this year.$3.32$0.07$3.25$1.81$2.51$0.70
2017Detailed filing. Detailed filing data is available for this year.$2.58$0.08$2.50$2.62$2.64$0.02
2016Detailed filing. Detailed filing data is available for this year.$2.59$0.07$2.52$1.62$2.69$1.07
2015Detailed filing. Detailed filing data is available for this year.$3.61$0.02$3.59$2.23$2.42$0.19
2014Detailed filing. Detailed filing data is available for this year.$3.81$0.03$3.78$4.42$2.48$1.94
2013Detailed filing. Detailed filing data is available for this year.$1.88$0.04$1.84$1.46$2.44$0.98
2012Summary only. Only limited summary data is available for this year.$2.85$0.03$2.83$2.04$1.87$0.17
2011Summary only. Only limited summary data is available for this year.$2.68$0.02$2.66$1.89$1.68$0.21
2010Summary only. Only limited summary data is available for this year.$2.25$0.00$2.25$1.91$2.20$0.29